A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Neoplasms|Breast Neoplasms
Interventions: DRUG: talazoparib
Sponsor: Pfizer